Deciphering Dengue Fever (DF)： Understanding it and preventing it.

On the evening of September 19th, local time, the Embassy of China in Vietnam issued a notice to remind citizens in China to take precautions against dengue fever. Recently, the confirmed cases of dengue fever in Vietnam have increased rapidly. During the week from September 4th to 10th, there were 5,180 confirmed cases in Vietnam, including one death (in Heping Province), and the number of confirmed cases in ha noi reached 2010, nearly double that in the last week of August. Since the beginning of the year, the cumulative number of confirmed cases in Vietnam has reached 81,808, including 23 deaths. The Embassy in Vietnam reminds citizens in China to take precautions.

According to reports, at present, dengue fever outbreaks have occurred in many places around the world:

According to the data released by Taiwan Province’s "Disease Control Department", as of September 17, 8,358 cases of dengue fever have been diagnosed in Taiwan this year, and 11 cases have died;

According to the China Embassy in Singapore’s WeChat WeChat official account news, according to the Singapore Environment Agency (NEA) news, 259 cases of dengue fever (locally known as "bone pain fever") were found in Singapore within one week, and the number of cases showed an upward trend.

According to the CCTV news client, the data released by the General Administration of Health Services of Bangladesh on September 16 showed that as of that date, the country had reported a total of 164,562 cases of dengue fever and 804 deaths this year. According to the World Health Organization, this is the worst dengue fever epidemic ever recorded in the country.

According to CCTV news reports, Thai Ministry of Health officials said on September 20 that the latest report of the Department of Disease Control of the Ministry of Health showed that from the beginning of 2023 to September 13, 91,979 cases of dengue infection were found in Thailand, with 84 cumulative deaths.

Controlling the media and preventing mosquito bites are important measures to prevent dengue virus infection. Insecticide disinfection has been widely used for mosquito control. However, due to pesticide resistance and other reasons, the number of mosquitoes is mainly controlled by clearing mosquito breeding sites, carrying out publicity and education to enhance residents’ awareness of cleaning mosquito breeding sites themselves, and improving environmental sanitation conditions.

There is no safe and effective dengue virus vaccine for vaccination. DEN1~4 mixed attenuated live vaccine has a certain immune effect. However, the stability of the attenuated strain is poor, which may cause clinical symptoms and DHF and DSS caused by Antibody-Dependent Enhancement (ADE). It is generally believed that NS1, a non-structural protein, can not induce ADE, so it is possible to obtain satisfactory immune effect by using DNA recombination technology to prepare NS1 subunit vaccine or genetic engineering vaccine.

The envelope protein E and recombinant protein antibody of dengue virus are antibodies against dengue virus, which can mediate the combination and invasion of virus and host cell membrane. These antibodies can be applied by vaccines or drugs to provide passive immune protection. Injecting this antibody into patients before or at the early stage of infection can immediately neutralize the virus and reduce the replication and spread of the virus in the body, thus reducing the development and severity of the disease.

Dengue fever is a mosquito-borne disease, and its prevention and control need many efforts. At present, when there is no fully effective vaccine, we can make positive progress in the prevention and treatment of dengue fever by controlling mosquito transmission, raising residents’ awareness of cleaning breeding sites, and researching and developing new vaccines and antibody applications. Continued research efforts and public participation will help to reduce the incidence of dengue fever and ensure people’s health and safety.

RVV04001

Anti-DENV-2 E-DII/Envelope Protein E Antibody (2A10)

RVV04201

Anti-Dengue Virus NS1 antibody

VVV25303

InVivoMAb Anti-DENV2 Protein prM/prM Antibody (2H2)

YVV15801

Recombinant DENV-2 NS1/Non-structural protein 1 Protein, N-His

RVV04002

Anti-DENV-2 E-DII/Envelope Protein E Antibody (2A10)

VVV19902

InVivoMAb Anti-DENV-2 Envelope protein E/EDIII (Iv0125)

VVV19901

InVivoMAb Anti-DENV-2 Envelope protein E/EDIII (Iv0124)

YVV19905

Recombinant DENV-1 Envelope protein E, N-His

YVV19904

Recombinant DENV-4 Envelope protein E, N-His

YVV19903

Recombinant DENV-2 Envelope protein E, N-His

YVV19902

Recombinant DENV-3 Envelope protein E, N-His

YVV19901

Recombinant DENV-2 Envelope protein E, N-His

RVV11701

Anti-Dengue and Zika virus EDE1 Antibody (EDE1C10)

RVV04101

Anti-DENV-2 E-DIII antibody (1A1D)